Acylated heptapeptide binds albumin with high affinity and application as tag furnishes long-acting peptides

A major challenge for the application of peptide therapeutics is their short half-lifein vivo. Here, the authors design peptide-fatty acid chimeras bearing an engineered linker that promotes albumin binding and allows longer circulation times of therapeutic peptides in animal models.

Guardado en:
Detalles Bibliográficos
Autores principales: Alessandro Zorzi, Simon J. Middendorp, Jonas Wilbs, Kaycie Deyle, Christian Heinis
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2017
Materias:
Q
Acceso en línea:https://doaj.org/article/cb4c3effd8b24083a11b07d420333e2b
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:A major challenge for the application of peptide therapeutics is their short half-lifein vivo. Here, the authors design peptide-fatty acid chimeras bearing an engineered linker that promotes albumin binding and allows longer circulation times of therapeutic peptides in animal models.